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Available online 11 February 2016The Genea067 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying expansion of CTG repeats in the DMPK gene, indicative of Myotonic Dystrophy Type 1
(DM1). Following ICM outgrowth on inactivated human feeders, karyotype was conﬁrmed as 46, XY and STR
analysis demonstrated a male Allele pattern. The hESC line had pluripotent cell morphology, 85% of cells
expressed Nanog, 97%Oct4, 73% Tra1-60 and 98% SSEA4 and gave a Pluritest Pluripotency score of 25.75, Novelty
of 1.46. The cell line was negative forMycoplasma and visible contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(continued)Resource table
Dame of stem cell line Genea067— DM1 affected (Alternate ID: SIVF067)
stitution Genea BiocellsSterson who created resource Biljana Dumevska
ontact person and email biljana.dumevska@geneabiocells.com
ate archived/stock date November, 2010
rigin Human Embryos
pe of resource Derived human embryonic stem cell line
b-type DM1 affected human pluripotent cell line
ey marker expression Nanog, Oct4, Tra1-60, and SSEA4
uthentication Identity and purity of cell line conﬁrmed
(Figs. 1–2 and Tables 1–2 below)
nk to related literature (direct
URL links and full references)
formation in public databases National Institutes of Health registered, NIH:
NIHhESC-12-0190
UK Stem Cell Bank registered, UKSCB: SCSC14-50thical approval Obtained from the Genea Ethics Committee
on 13 September 2005 under the Australian
National Health and Medical Research Council
(NHMRC) licence 309710Resource detailsate of derivation October 2010
aryotype 46, XY
x Male
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4
staining and Pluritest(B. Dumevska).
. This is an open access article under theisease statusCC BY-NC-ND license (http://createxpansion of CTG repeat in DMPK gene —
Myotonic Dystrophy 1 (DM1) affected,
OMIM: 160900erility The cell line is tested and found negative
for Mycoplasma and any visible contaminationbling lines available NOSiMaterials and methods
Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and plated
onto mitomycin C inactivated human feeders (Detroit 551 HFF —
90,000/well in 4-well) in 20% Knock out serum in standard hESC culture
medium (Amit et al., 2000) with 20 ng/mL Fgf2. CGH karyotyping and
STR proﬁling were performed at the ﬁrst cryobanking step from ICM
outgrowths maintained on feeders. Cells were then enzymatically
passaged as single cells in M2 pluripotent cell maintenance medium
(Genea Biocells) and CGH/karyotyping repeated, immunoﬂuorescent
pluripotent marker staining, Pluritest and sterility testing performed.
Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal analysis:
Passage 3; CGHwas used to screen targeted regions of the genome for
gains and losses associated with chromosomal imbalances such as
aneuploidy, deletions and duplications. CGH was performed using
SurePrint G3 microarrays (8x 60K format) which were scanned with
the Agilent Scanner C and analysed using Genomic Workbench
Standard Edition 5.0 software (Agilent Technologies).
2. DNAProﬁling: Passage 3; DNA ‘ﬁngerprinting’wasperformedusing the
AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystemsivecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Morphology of Genea067. Brightﬁeld (passage 1) growing on human inactivated
feeders.
Table 1
CGH analysis summary; Genea067 (passage 3) reporting amale cell line andno abnormal-
ities detected.
CGH summary
Sample name SIVF 067p3
Date reported 7th December 2010
Hybridisation balance Balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N200 kb were detected
Interpretation Male cell line — no abnormalities detected
438 B. Dumevska et al. / Stem Cell Research 16 (2016) 437–439#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/4322288Table 2
STR proﬁle; Genea067 (passage 3) demonstrating male Allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317
SIVF067p3 13,15 28,30 8,10 13,14 16,18 6,9.3 11
Fig. 2. Pluripotency validation of Genea067. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest Pluripotency (lePluripotency assessment
1. Immunoﬂuorescence: Passage 7 (5 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; and SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (5 on feeders, 3 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
Sterility testing
1. Mycoplasma: Passage 9 (6 on feeders, 3 enzymatic); testing was
performed as per manufacturer's instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA.
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsibleD16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
9,12 17,20 13 16 9,11 17,18 11,13 20,23
t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 7, 2
ft) and Novelty (right) scores with Genea067 (passage 8, 3 enzymatic) outlined in black.
439B. Dumevska et al. / Stem Cell Research 16 (2016) 437–439people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea067 has been
derived from a donated, fully commercially consented embryo, original-
ly created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation ge-
netic diagnosis to be affected by a genetic mutation and was declared
excess to reproductive needs. Derivation was performed under
Australian National Health and Medical Research Council (NHMRC)
licence 309710. This licence was issued to GENEA on 7 May 2007.
More information about the licence can be obtained from the NHMRC
webpage at http://www.nhmrc.gov.au/health-ethics/human-embryos-
and-cloning/database-licences-authorising-use-excess-art-embryos.
PGD analysis conclusion
Mutation; expansion of CTG repeat in DMPK gene. Family tree;
Mother; b inherited from her Father. Myotonic Dystrophy 1 (DM1)
affected.
Morphology
The derived stem cell line, Genea067, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1).
Genetic analysis
The cell line has been karyotype tested by CGH (Table 1, Supplemen-
tary Fig. 1), which demonstrated 46, XY karyotype, consistent withoriginal derivation and pre-implantation genetic diagnosis (PGD).
Analysis of STR markers showed Allele pattern consistent with male
genotype (Table 2, Supplementary Fig. 2).
Pluripotency
GENEA067 is pluripotent by;
1. Immunoﬂuorescence with 85% Nanog positive, 97% Oct4 positive,
73% Tra1-60 positive and 98% SSEA4 positive (Fig. 2A, quantiﬁed in
Fig. 2B).
2. Pluritest with a Pluripotency score of 25.75 and Novelty score of 1.46
(Fig. 2C).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.014.
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